Teprotumumab for the treatment of thyroid eye disease.

IF 3.7 3区医学 Q2 IMMUNOLOGY Expert Review of Clinical Immunology Pub Date : 2020-08-01 Epub Date: 2020-08-09 DOI:10.1080/1744666X.2020.1801421

Yongjing Ju, Junyi Yang

{"title":"Teprotumumab for the treatment of thyroid eye disease.","authors":"Yongjing Ju, Junyi Yang","doi":"10.1080/1744666X.2020.1801421","DOIUrl":null,"url":null,"abstract":"Introduction: Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease.Areas covered: The authors performed a systematic review of the literature using the PubMed database, and the following keywords were used: 'teprotumumab,' 'thyroid eye disease,' and 'insulin-like growth factor I receptor.' The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of teprotumumab were introduced in this paper.Expert opinion: Teprotumumab is a human monoclonal antibody targeting insulin-like growth factor-I receptor. Clinical trials indicated that proptosis response of teprotumumab was 83%, and clinical activity score, diplopia, and quality of life were also better than placebo. Teprotumumab was well tolerated, common adverse reactions included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":"16 8","pages":"739-743"},"PeriodicalIF":3.7000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/1744666X.2020.1801421","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2020.1801421","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 6

Abstract

Introduction: Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease.

Areas covered: The authors performed a systematic review of the literature using the PubMed database, and the following keywords were used: 'teprotumumab,' 'thyroid eye disease,' and 'insulin-like growth factor I receptor.' The chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of teprotumumab were introduced in this paper.

Expert opinion: Teprotumumab is a human monoclonal antibody targeting insulin-like growth factor-I receptor. Clinical trials indicated that proptosis response of teprotumumab was 83%, and clinical activity score, diplopia, and quality of life were also better than placebo. Teprotumumab was well tolerated, common adverse reactions included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Teprotumumab用于治疗甲状腺眼病。

简介:甲状腺眼病是一种使人衰弱、毁容和潜在致盲的眼周疾病。Teprotumumab是一种人胰岛素样生长因子- 1受体单克隆抑制剂抗体，用于治疗甲状腺眼病。涵盖领域:作者使用PubMed数据库对文献进行了系统回顾，使用了以下关键词:“teprotumumab”、“甲状腺眼病”和“胰岛素样生长因子I受体”。本文介绍了teprotumumab的化学性质、作用机制、药代动力学、临床疗效和安全性。专家意见:Teprotumumab是一种靶向胰岛素样生长因子- 1受体的人单克隆抗体。临床试验表明，teprotumumab的预后反应为83%，临床活动评分、复视和生活质量也优于安慰剂。Teprotumumab耐受性良好，常见的不良反应包括肌肉痉挛、恶心、脱发、腹泻、疲劳、高血糖、听力障碍、认知障碍、头痛和皮肤干燥。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.